Eli Lilly's most recent trend suggests a bullish bias. One trading opportunity on Eli Lilly is a Bull Put Spread using a strike $115.00 short put and a strike $110.00 long put offers a potential 32.63% return on risk over the next 8 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $115.00 by expiration. The full premium credit of $1.23 would be kept by the premium seller. The risk of $3.77 would be incurred if the stock dropped below the $110.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Eli Lilly is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Eli Lilly is bullish.
The RSI indicator is at 65.43 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
Would-Be Dealmakers Warn of M&A, IPO Delays Due to Shutdown
Wed, 09 Jan 2019 00:16:17 +0000
A prolonged shutdown could muddle Eli Lilly & Co.’s plan to unload its stake in Elanco Animal Health Inc., the unit it spun off last year, Lilly Chief Executive Officer Dave Ricks said in an interview Tuesday. “People typically go out in early January with IPOs because if you price after Feb. 14, you need your audit for 2018,” said David Goldschmidt, global head of capital markets at Skadden Arps Slate Meagher & Flom LLP. Other deals that might be affected by the shutdown that began Dec. 22 include:Eclipse Resources Corp. and Blue Ridge Mountain Resources Inc. extended the termination date of their roughly $900 million merger “to provide the parties additional flexibility in light of the shutdown of portions of the U.S. federal government,” according to a regulatory filing Tuesday.
Eli Lilly giving price info on advertised drugs via website
Tue, 08 Jan 2019 22:27:16 +0000
Drugmaker Eli Lilly has started posting price information online for drugs advertised on TV.
Why Eli Lilly Is Buying Loxo Oncology for $8 Billion
Tue, 08 Jan 2019 22:01:00 +0000
The pharmaceutical giant is making a big bet on this cancer-drug upstart.
WEISSLAW LLP: Loxo Oncology, Inc. Acquisition May Not Be In The Best Interests of LOXO Shareholders
Tue, 08 Jan 2019 20:12:00 +0000
NEW YORK , Jan. 8, 2019 /PRNewswire/ — WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Loxo Oncology, Inc. (“LOXO” …
Loxo Oncology Is Expected to Boost Eli Lilly’s Revenue in 2019
Tue, 08 Jan 2019 16:30:02 +0000
Eli Lilly and Company (LLY) expects its Loxo Oncology (LOXO) acquisition to become revenue accretive starting in 2019. Analysts expect Loxo to report revenue of $178.30 million in 2018, a YoY (year-over-year) rise of 737.08%. The company is also expected to report revenue of $197.96 million in 2019, a YoY rise of 11.03%.
Also on Market Tamer…
Follow Us on Facebook